BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Glycominds Ltd. Achieves CE MARK For Novel Crohn's Disease Blood Test; US Patent Office Grants GlycoChip Letters Of Allowance


10/19/2005 5:09:48 PM

LOD, Israel--(BUSINESS WIRE)--May 25, 2005--Glycominds announced today that it has achieved the CE MARK of the EU for the marketing of the company's IBDX(TM) products. The IBDX kit is a series of blood tests for Crohn's Disease, enabling differential diagnosis between Crohn's Disease, Ulcerative Colitis and Irritable Bowel Syndrome. "For the first time there is now a highly-reliable way for doctors to test patients presenting with the very similar symptoms that occur in chronic gastrointestinal conditions," said Avinoam Dukler, Glycominds CEO. "We expect the IBDX(TM) to revolutionize the way in which these conditions are diagnosed. This product line is a significant advance over existing tests, offering a simple non-invasive blood test with improved sensitivity and specificity. The IBDX(TM) kits have nearly 80 percent sensitivity compared to the 50 percent level common in existing tests. In addition, using two different IBDX(TM) markers together increases specificity to 99 percent."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES